Arcturus Therapeutics double downgraded to sell by Roth

 

• Arcturus Therapeutics (ARCT -10.3%) price affected after double downgraded after Roth Capital analyst Elemer Piros to Sell from Buy.
• While there could be a number of advantages to Arcturus' Covid vaccine, including a lower dose, potential single dose and storage advantage, the efficacy bar is 'significant' at over 90%, Piros tells investors in a research note.
• Price target unchanged $77.
• With the stock now significantly above the price target, the analyst downgrades Arcturus to Sell pending further information on the vaccine program.
• https://seekingalpha.com/news/3647070-arcturus-therapeutics-double-downgraded-to-sell-roth-capital-stock-slumps-11